ArticleBMC cardiovascular disorders2026
Development and validation of a nomogram to predict the risk of cardiometabolic multimorbidity in older adults: data from the NHANES database.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a nomogram prediction model for predicting the risk of cardiometabolic multimorbidity(CMM) in older adults, providing a basis for early risk stratification and clinical intervention.
methodsData from seven survey cycles (2005–2018) of the NHANES database were integrated, incorporating 6,338 older adults aged ≥ 65 years who met the inclusion criteria. LASSO regression was employed to screen characteristic variables associated with CMM, followed by multivariate logistic regression analysis to identify independent risk factors and construct the model. The model’s performance was evaluated using the receiver operating characteristic (ROC) curve (AUC) for discrimination, Spiegelhalter’s z-test for calibration, and Decision Curve Analysis (DCA) for clinical utility.
resultsLASSO regression identified 10 characteristic variables, all of which were confirmed as independent predictors via multivariate logistic regression: college education or above (OR = 0.731, 95% CI: 0.611–0.873, P = 0.001), waist circumference (OR = 1.026, 95% CI: 1.021–1.030, P < 0.001), poverty-income ratio > 3 (OR = 0.750, 95% CI: 0.622–0.904, P = 0.003), Patient Health Questionnaire-9 (PHQ-9) score (OR = 1.057, 95% CI: 1.041–1.073, P < 0.001), high-density lipoprotein cholesterol (OR = 0.682, 95% CI: 0.585–0.796, P < 0.001), hemoglobin (OR = 0.884, 95% CI: 0.847–0.922, P < 0.001), red blood cell distribution width (OR = 1.052, 95% CI: 1.005–1.102, P = 0.030), blood urea nitrogen (OR = 1.104, 95% CI: 1.079–1.130, P < 0.001), globulin (OR = 1.026, 95% CI: 1.014–1.038, P < 0.001), and total cholesterol (OR = 0.644, 95% CI: 0.608–0.681, P < 0.001). The AUC of the nomogram was 0.735 (95% CI: 0.723–0.748), and internal 10-fold cross-validation yielded a consistent AUC of 0.736 (95% CI: 0.721–0.748). Spiegelhalter’s z-test (z=-0.399, P = 0.655) indicated good calibration. DCA showed a positive net benefit when the threshold probability for CMM was between 15% and 77%.
conclusionThe nomogram demonstrates satisfactory predictive performance CMM risk in older adults and serves as a valuable quantitative tool for individualized prevention and control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.